<?xml version="1.0" encoding="UTF-8"?>
<p>The TRIPS Agreement, however, provides governments with some flexibility in managing patents for public goods such as pharmaceuticals. In particular, the Doha Declaration on the TRIPS Agreement and Public Health in November 2001 highlights and clarifies a key flexibility afforded to countries in Article 31 of the TRIPS agreement: the right to grant compulsory licenses. Compulsory licensing refers to the use of a patent without the authorization of the patent holder. Specifically, issuing a compulsory license for a pharmaceutical treatment allows a government to locally manufacture or import generic versions of the treatment without the patent holderâ€™s consent.</p>
